Loading…

Octreotide in the management of postoperative chylothorax

Chylothorax (KT) may be a complication of thoracic surgery. Its management is not well established and may comprise dietary interventions and surgery. The effectiveness of somatostatin and its analogues has been reported, although their mechanism(s) of action is unclear. We report our experience wit...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric cardiology 2005-08, Vol.26 (4), p.440-443
Main Authors: Rosti, L, De Battisti, F, Butera, G, Cirri, S, Chessa, M, Delogu, A, Drago, M, Giamberti, A, Pomè, G, Carminati, M, Frigiola, A
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c404t-8e6949c4f2529af98a8c470ef76672027201e8206233ba9a7747a1838d5d81ce3
cites cdi_FETCH-LOGICAL-c404t-8e6949c4f2529af98a8c470ef76672027201e8206233ba9a7747a1838d5d81ce3
container_end_page 443
container_issue 4
container_start_page 440
container_title Pediatric cardiology
container_volume 26
creator Rosti, L
De Battisti, F
Butera, G
Cirri, S
Chessa, M
Delogu, A
Drago, M
Giamberti, A
Pomè, G
Carminati, M
Frigiola, A
description Chylothorax (KT) may be a complication of thoracic surgery. Its management is not well established and may comprise dietary interventions and surgery. The effectiveness of somatostatin and its analogues has been reported, although their mechanism(s) of action is unclear. We report our experience with octreotide in a series of patients with postoperative chylothorax. Eight patients with KT were treated with a continuous intravenous infusion of octreotide (OCT) at a starting dose of 0.5 microg/kg/hr. They were compared with four additional patients with KT who were treated according to the conventional approach. After a mean of 3.3 +/- 1.9 days of treatment, fluid discharge diminished dramatically. In all patients, fluid losses stopped by postoperative day 10.5 +/- 2.9 and chest tubes could be removed after 12.8 +/- 4.1 days. Compared to a small group of historical controls, OCT reduced significantly the total fluid losses (141.1 +/- 89.3 vs 396.7 +/- 151.0 ml/kg; p = 0.003) and the postoperative length of stay (p = 0.05). No patients in the group treated with OCT required parenteral nutrition (compared to all four of the controls; p = 0.002) and/or thoracenteses (compared to two of four controls). In postoperative KT, OCT seems to be at least as effective as the conventional approach. Furthermore, OCT may reduce total fluid losses and postoperative length of stay. This may have a beneficial effect on the risk of complications and on hospital costs.
doi_str_mv 10.1007/s00246-004-0820-4
format article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_68918692</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A152066810</galeid><sourcerecordid>A152066810</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-8e6949c4f2529af98a8c470ef76672027201e8206233ba9a7747a1838d5d81ce3</originalsourceid><addsrcrecordid>eNptkdtKAzEQhoMoWg8P4I0sCN5FJ9k0h0sRTyB4o9chZmfbld1NTVKxb29KCyKUEALD92dm-Ag5Z3DNANRNAuBCUgBBQXOgYo9MmKg5ZUaxfTIBpjgFKeojcpzSJwBo0NNDcsRkrYQ0YkLMq88RQ-4arLqxynOsBje6GQ445iq01SKkHBYYXe6-sfLzVR_yPET3c0oOWtcnPNu-J-T94f7t7om-vD4-392-UC9AZKqx9DFetHzKjWuNdtoLBdgqKRUHXi7DMrzkdf3hjFNKKMd0rZtpo5nH-oRcbf5dxPC1xJTt0CWPfe9GDMtkpTZMS8MLeLkBZ65H241tyNH5NWxv2bR0kJpBoegOaoZjWbEPI7ZdKf_jr3fw5TQ4dH5ngG0CPoaUIrZ2EbvBxZVlYNfa7EabLdrsWpsVJXOx3XH5MWDzl9h6qn8BTiyPbA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68918692</pqid></control><display><type>article</type><title>Octreotide in the management of postoperative chylothorax</title><source>Springer Nature</source><creator>Rosti, L ; De Battisti, F ; Butera, G ; Cirri, S ; Chessa, M ; Delogu, A ; Drago, M ; Giamberti, A ; Pomè, G ; Carminati, M ; Frigiola, A</creator><creatorcontrib>Rosti, L ; De Battisti, F ; Butera, G ; Cirri, S ; Chessa, M ; Delogu, A ; Drago, M ; Giamberti, A ; Pomè, G ; Carminati, M ; Frigiola, A</creatorcontrib><description>Chylothorax (KT) may be a complication of thoracic surgery. Its management is not well established and may comprise dietary interventions and surgery. The effectiveness of somatostatin and its analogues has been reported, although their mechanism(s) of action is unclear. We report our experience with octreotide in a series of patients with postoperative chylothorax. Eight patients with KT were treated with a continuous intravenous infusion of octreotide (OCT) at a starting dose of 0.5 microg/kg/hr. They were compared with four additional patients with KT who were treated according to the conventional approach. After a mean of 3.3 +/- 1.9 days of treatment, fluid discharge diminished dramatically. In all patients, fluid losses stopped by postoperative day 10.5 +/- 2.9 and chest tubes could be removed after 12.8 +/- 4.1 days. Compared to a small group of historical controls, OCT reduced significantly the total fluid losses (141.1 +/- 89.3 vs 396.7 +/- 151.0 ml/kg; p = 0.003) and the postoperative length of stay (p = 0.05). No patients in the group treated with OCT required parenteral nutrition (compared to all four of the controls; p = 0.002) and/or thoracenteses (compared to two of four controls). In postoperative KT, OCT seems to be at least as effective as the conventional approach. Furthermore, OCT may reduce total fluid losses and postoperative length of stay. This may have a beneficial effect on the risk of complications and on hospital costs.</description><identifier>ISSN: 0172-0643</identifier><identifier>EISSN: 1432-1971</identifier><identifier>DOI: 10.1007/s00246-004-0820-4</identifier><identifier>PMID: 16374694</identifier><language>eng</language><publisher>United States: Springer</publisher><subject>Antineoplastic Agents, Hormonal - administration &amp; dosage ; Antineoplastic Agents, Hormonal - therapeutic use ; Chest ; Child ; Child, Preschool ; Chylothorax ; Chylothorax - drug therapy ; Chylothorax - etiology ; Complications and side effects ; Diagnosis ; Drug therapy ; Female ; Follow-Up Studies ; Humans ; Infant ; Infusions, Intravenous ; Length of Stay ; Male ; Octreotide - administration &amp; dosage ; Octreotide - therapeutic use ; Octreotide acetate ; Postoperative Complications ; Prospective Studies ; Surgery ; Thoracic Surgical Procedures - adverse effects ; Treatment Outcome</subject><ispartof>Pediatric cardiology, 2005-08, Vol.26 (4), p.440-443</ispartof><rights>COPYRIGHT 2005 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c404t-8e6949c4f2529af98a8c470ef76672027201e8206233ba9a7747a1838d5d81ce3</citedby><cites>FETCH-LOGICAL-c404t-8e6949c4f2529af98a8c470ef76672027201e8206233ba9a7747a1838d5d81ce3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16374694$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rosti, L</creatorcontrib><creatorcontrib>De Battisti, F</creatorcontrib><creatorcontrib>Butera, G</creatorcontrib><creatorcontrib>Cirri, S</creatorcontrib><creatorcontrib>Chessa, M</creatorcontrib><creatorcontrib>Delogu, A</creatorcontrib><creatorcontrib>Drago, M</creatorcontrib><creatorcontrib>Giamberti, A</creatorcontrib><creatorcontrib>Pomè, G</creatorcontrib><creatorcontrib>Carminati, M</creatorcontrib><creatorcontrib>Frigiola, A</creatorcontrib><title>Octreotide in the management of postoperative chylothorax</title><title>Pediatric cardiology</title><addtitle>Pediatr Cardiol</addtitle><description>Chylothorax (KT) may be a complication of thoracic surgery. Its management is not well established and may comprise dietary interventions and surgery. The effectiveness of somatostatin and its analogues has been reported, although their mechanism(s) of action is unclear. We report our experience with octreotide in a series of patients with postoperative chylothorax. Eight patients with KT were treated with a continuous intravenous infusion of octreotide (OCT) at a starting dose of 0.5 microg/kg/hr. They were compared with four additional patients with KT who were treated according to the conventional approach. After a mean of 3.3 +/- 1.9 days of treatment, fluid discharge diminished dramatically. In all patients, fluid losses stopped by postoperative day 10.5 +/- 2.9 and chest tubes could be removed after 12.8 +/- 4.1 days. Compared to a small group of historical controls, OCT reduced significantly the total fluid losses (141.1 +/- 89.3 vs 396.7 +/- 151.0 ml/kg; p = 0.003) and the postoperative length of stay (p = 0.05). No patients in the group treated with OCT required parenteral nutrition (compared to all four of the controls; p = 0.002) and/or thoracenteses (compared to two of four controls). In postoperative KT, OCT seems to be at least as effective as the conventional approach. Furthermore, OCT may reduce total fluid losses and postoperative length of stay. This may have a beneficial effect on the risk of complications and on hospital costs.</description><subject>Antineoplastic Agents, Hormonal - administration &amp; dosage</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Chest</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Chylothorax</subject><subject>Chylothorax - drug therapy</subject><subject>Chylothorax - etiology</subject><subject>Complications and side effects</subject><subject>Diagnosis</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Infant</subject><subject>Infusions, Intravenous</subject><subject>Length of Stay</subject><subject>Male</subject><subject>Octreotide - administration &amp; dosage</subject><subject>Octreotide - therapeutic use</subject><subject>Octreotide acetate</subject><subject>Postoperative Complications</subject><subject>Prospective Studies</subject><subject>Surgery</subject><subject>Thoracic Surgical Procedures - adverse effects</subject><subject>Treatment Outcome</subject><issn>0172-0643</issn><issn>1432-1971</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNptkdtKAzEQhoMoWg8P4I0sCN5FJ9k0h0sRTyB4o9chZmfbld1NTVKxb29KCyKUEALD92dm-Ag5Z3DNANRNAuBCUgBBQXOgYo9MmKg5ZUaxfTIBpjgFKeojcpzSJwBo0NNDcsRkrYQ0YkLMq88RQ-4arLqxynOsBje6GQ445iq01SKkHBYYXe6-sfLzVR_yPET3c0oOWtcnPNu-J-T94f7t7om-vD4-392-UC9AZKqx9DFetHzKjWuNdtoLBdgqKRUHXi7DMrzkdf3hjFNKKMd0rZtpo5nH-oRcbf5dxPC1xJTt0CWPfe9GDMtkpTZMS8MLeLkBZ65H241tyNH5NWxv2bR0kJpBoegOaoZjWbEPI7ZdKf_jr3fw5TQ4dH5ngG0CPoaUIrZ2EbvBxZVlYNfa7EabLdrsWpsVJXOx3XH5MWDzl9h6qn8BTiyPbA</recordid><startdate>200508</startdate><enddate>200508</enddate><creator>Rosti, L</creator><creator>De Battisti, F</creator><creator>Butera, G</creator><creator>Cirri, S</creator><creator>Chessa, M</creator><creator>Delogu, A</creator><creator>Drago, M</creator><creator>Giamberti, A</creator><creator>Pomè, G</creator><creator>Carminati, M</creator><creator>Frigiola, A</creator><general>Springer</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200508</creationdate><title>Octreotide in the management of postoperative chylothorax</title><author>Rosti, L ; De Battisti, F ; Butera, G ; Cirri, S ; Chessa, M ; Delogu, A ; Drago, M ; Giamberti, A ; Pomè, G ; Carminati, M ; Frigiola, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-8e6949c4f2529af98a8c470ef76672027201e8206233ba9a7747a1838d5d81ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Antineoplastic Agents, Hormonal - administration &amp; dosage</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Chest</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Chylothorax</topic><topic>Chylothorax - drug therapy</topic><topic>Chylothorax - etiology</topic><topic>Complications and side effects</topic><topic>Diagnosis</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Infant</topic><topic>Infusions, Intravenous</topic><topic>Length of Stay</topic><topic>Male</topic><topic>Octreotide - administration &amp; dosage</topic><topic>Octreotide - therapeutic use</topic><topic>Octreotide acetate</topic><topic>Postoperative Complications</topic><topic>Prospective Studies</topic><topic>Surgery</topic><topic>Thoracic Surgical Procedures - adverse effects</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rosti, L</creatorcontrib><creatorcontrib>De Battisti, F</creatorcontrib><creatorcontrib>Butera, G</creatorcontrib><creatorcontrib>Cirri, S</creatorcontrib><creatorcontrib>Chessa, M</creatorcontrib><creatorcontrib>Delogu, A</creatorcontrib><creatorcontrib>Drago, M</creatorcontrib><creatorcontrib>Giamberti, A</creatorcontrib><creatorcontrib>Pomè, G</creatorcontrib><creatorcontrib>Carminati, M</creatorcontrib><creatorcontrib>Frigiola, A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rosti, L</au><au>De Battisti, F</au><au>Butera, G</au><au>Cirri, S</au><au>Chessa, M</au><au>Delogu, A</au><au>Drago, M</au><au>Giamberti, A</au><au>Pomè, G</au><au>Carminati, M</au><au>Frigiola, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Octreotide in the management of postoperative chylothorax</atitle><jtitle>Pediatric cardiology</jtitle><addtitle>Pediatr Cardiol</addtitle><date>2005-08</date><risdate>2005</risdate><volume>26</volume><issue>4</issue><spage>440</spage><epage>443</epage><pages>440-443</pages><issn>0172-0643</issn><eissn>1432-1971</eissn><abstract>Chylothorax (KT) may be a complication of thoracic surgery. Its management is not well established and may comprise dietary interventions and surgery. The effectiveness of somatostatin and its analogues has been reported, although their mechanism(s) of action is unclear. We report our experience with octreotide in a series of patients with postoperative chylothorax. Eight patients with KT were treated with a continuous intravenous infusion of octreotide (OCT) at a starting dose of 0.5 microg/kg/hr. They were compared with four additional patients with KT who were treated according to the conventional approach. After a mean of 3.3 +/- 1.9 days of treatment, fluid discharge diminished dramatically. In all patients, fluid losses stopped by postoperative day 10.5 +/- 2.9 and chest tubes could be removed after 12.8 +/- 4.1 days. Compared to a small group of historical controls, OCT reduced significantly the total fluid losses (141.1 +/- 89.3 vs 396.7 +/- 151.0 ml/kg; p = 0.003) and the postoperative length of stay (p = 0.05). No patients in the group treated with OCT required parenteral nutrition (compared to all four of the controls; p = 0.002) and/or thoracenteses (compared to two of four controls). In postoperative KT, OCT seems to be at least as effective as the conventional approach. Furthermore, OCT may reduce total fluid losses and postoperative length of stay. This may have a beneficial effect on the risk of complications and on hospital costs.</abstract><cop>United States</cop><pub>Springer</pub><pmid>16374694</pmid><doi>10.1007/s00246-004-0820-4</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0172-0643
ispartof Pediatric cardiology, 2005-08, Vol.26 (4), p.440-443
issn 0172-0643
1432-1971
language eng
recordid cdi_proquest_miscellaneous_68918692
source Springer Nature
subjects Antineoplastic Agents, Hormonal - administration & dosage
Antineoplastic Agents, Hormonal - therapeutic use
Chest
Child
Child, Preschool
Chylothorax
Chylothorax - drug therapy
Chylothorax - etiology
Complications and side effects
Diagnosis
Drug therapy
Female
Follow-Up Studies
Humans
Infant
Infusions, Intravenous
Length of Stay
Male
Octreotide - administration & dosage
Octreotide - therapeutic use
Octreotide acetate
Postoperative Complications
Prospective Studies
Surgery
Thoracic Surgical Procedures - adverse effects
Treatment Outcome
title Octreotide in the management of postoperative chylothorax
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T10%3A15%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Octreotide%20in%20the%20management%20of%20postoperative%20chylothorax&rft.jtitle=Pediatric%20cardiology&rft.au=Rosti,%20L&rft.date=2005-08&rft.volume=26&rft.issue=4&rft.spage=440&rft.epage=443&rft.pages=440-443&rft.issn=0172-0643&rft.eissn=1432-1971&rft_id=info:doi/10.1007/s00246-004-0820-4&rft_dat=%3Cgale_proqu%3EA152066810%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c404t-8e6949c4f2529af98a8c470ef76672027201e8206233ba9a7747a1838d5d81ce3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=68918692&rft_id=info:pmid/16374694&rft_galeid=A152066810&rfr_iscdi=true